Vertex Pharmaceuticals, Inc. (VRTX) Misses Q3 EPS by 6c
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q3 EPS of $0.13, $0.06 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $336 million versus the consensus estimate of $377.14 million.Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.